Perioperative Docetaxel, Oxaliplatin, Fluorouracil, and Leucovorin (FLOT) in Patients with Gastric or Esophagogastric Junction Adenocarcinoma; Real-Life Experience
[ X ]
Tarih
2020
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Akad Doktorlar Yayinevi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
In patients with gastic cancer, five-year survival is poor in the locally advanced stage. Docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil (FLOT) combination regimen has been shown to provide a survival advantage in the locally advanced stage. In this study, we aimed to evaluate the efficacy and tolerability of FLOT with real-life data in patients with locally advanced gastric/esophagogastric junction cancers. This retrospective study was conducted between June 2016 - March 2020 and included 106 patients' data from six centers in Turkey. Median age was 60 (33-82). Primary tumor localization was stomach in 76 (71.7%) patients. Seventy-six (71.7%) patients were operated after median 4 (1-8 cycles) cycles of preoperative FLOT. Pathological complete regression (pCR)was obtained in 10 (13.1%) of the operated patients. Median follow-up was 9.1 (1.4-45.7) months. One-year DFS was 63.2% and the two-year OS was 65.1%. Three (2.8%) patients had chemotherapy-related deaths. Due to chemotherapy-related toxicity and intoleration, 19 (17.9%) patients had dose reduction. The pCR obtained by FLOT appears higher than other regimens. This study is one of the rare mufticentric real-life data showing the efficacy and tolerability of the FLOT regimen in the perioperative treatment in GC and EJC.
Açıklama
Anahtar Kelimeler
Gastric Cancer, Perioperative Chemotherapy, Neoadjuvant Chemotherapy, Flot, Locally Advanced Gastric Cancer
Kaynak
Uhod-Uluslararasi Hematoloji-Onkoloji Dergisi
WoS Q Değeri
Q4
Scopus Q Değeri
Cilt
30
Sayı
3
